KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Rigel Pharmaceuticals (RIGL) over the last 10 years, with Q3 2025 value amounting to $4.8 million.

  • Rigel Pharmaceuticals' Other Operating Expenses fell 4078.0% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 1686.09%. This contributed to the annual value of $18.6 million for FY2024, which is 16226.44% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Other Operating Expenses is $4.8 million, which was down 4078.0% from $4.5 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Other Operating Expenses' 5-year high stood at $8.0 million during Q3 2024, with a 5-year trough of $121000.0 in Q1 2022.
  • Moreover, its 5-year median value for Other Operating Expenses was $1.7 million (2022), whereas its average is $2.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 114859.81% in 2021, then plummeted by 6170.89% in 2022.
  • Rigel Pharmaceuticals' Other Operating Expenses (Quarter) stood at $4.0 million in 2021, then plummeted by 58.53% to $1.7 million in 2022, then surged by 128.04% to $3.8 million in 2023, then skyrocketed by 52.74% to $5.8 million in 2024, then decreased by 17.9% to $4.8 million in 2025.
  • Its Other Operating Expenses stands at $4.8 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.4 million for Q1 2025.